期刊
BONE MARROW TRANSPLANTATION
卷 50, 期 1, 页码 127-133出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/bmt.2014.223
关键词
-
资金
- Beijing Municipal Science and Technology Program [Z111107067311070]
- Clinical Characteristic Study of Capital Project [Z121107001012085]
- Key Program of the National Natural Science Foundation of China [81230013]
The aim of this study was to investigate the impact of occurrence of chronic GVHD (cGVHD) and its severity on transplantation outcomes in a consecutive cohort of AML and myelodysplastic syndrome (MDS) patients who received unmanipulated haploidentical hematopoietic SCT (haplo-HSCT; n = 324). The cumulative incidence of relapse was significantly decreased in patients with cGVHD compared with the non-cGVHD group (1 year: 3.2% vs 11.9%, P = 0.002; 3 years: 6.0% vs 16.3%, P = 0.002), particularly in those with mild cGVHD. The cumulative incidence of non-relapse mortality was comparable between patients with and without cGVHD. The probabilities of disease-free survival (DFS) were significantly better in patients with cGVHD than in those in the non-cGVHD group (1 year: 90.5% vs 78.5%, P = 0.002; 3 years: 86.5% vs 71.5%, P < 0.001), particularly in those with mild or moderate cGVHD; however, no significant impact of severe cGVHD on DFS was seen. Our findings highlight the close relationship between cGVHD and the immune-mediated GVL effect in patients with AML and MDS receiving unmanipulated haplo-HSCT; however, only mild or moderate cGVHD was associated with a lower risk of relapse translating into improved DFS.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据